284
Participants
Start Date
May 10, 2019
Primary Completion Date
June 11, 2024
Study Completion Date
June 11, 2024
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
CUB Hôpital Erasme, Brussels
Medizinische Universität Wien, Vienna
Klinikum Wels-Grieskirchen GmbH, Wels
Hospital de la Santa Creu i Sant Pau, Barcelona
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Berlin
National Cancer Center, Goyang-si
NYU Langone Health, New York
Stony Brook University, Stony Brook
SUNY Upstate Medical University, Syracuse
Seoul National University Budang Hospital, Seongnam-si
Allegheny General Hospital, Pittsburgh
Institut Catalá d'Oncologia (ICO Girona). Hospital Dr. Josep Trueta, Girona
Thomas Jefferson University, Philadelphia
Reading Hospital McGlinn Cancer Institute, West Reading
Istituto Clinico Humanitas, Rozzano
IRCCS Ospedale San Raffaele, Milan
Istituto Europeo di Oncologia, Milan
Grande Ospedale Metropolitano Niguarda, Oncologia Medica Falck, Milan
Centre Georges-François Leclerc, Dijon
Inova Schar Cancer Institute, Fairfax
CHRU Jean Minjoz, Besançon
West Virginia University, Morgantown
Hospital General Universitario Gregorio Marañon, Madrid
MD Anderson Cancer Center, Madrid
Hospital Clinico San Carlos, Madrid
Haut-Lévêque, Pessac
Alvaro Cunqueiro Hospital, Vigo
CRC di Verona, Verona
CHU Grenoble Alpes, La Tronche
Norton Cancer Institute, Audubon Hospital Campus, Louisville
Ohio State University, Columbus
Institut de Cancérologie de l'Ouest Pays de Loire, Saint-Herblain
University of Cincinnati Medical Center, Cincinnati
Hospital Clinico Universitario de Valencia, Valencia
Instituto Scientifico Romagnolog per lo Studio e la Cura dei Tumori, Meldola
University of Michigan, Ann Arbor
Karmanos Cancer Institute, Detroit
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Hospital Universitario Miguel Servet, Zaragoza
Chonnam National University Hwasun Hospital, Hwasun
Elmhurst Memorial Hospital - Nancy W. Knowles Cancer Center, Elmhurst
Edward Cancer Center, Naperville
CHU Estaing, Clermont-Ferrand
Saint Luke's Hospital, Kansas City
University of Kansas Hospital, Westwood
University of Nebraska Medical Center, Omaha
Centre Léon Bérard, Lyon
Hôpital Edouard Herriot, Lyon
Baylor Scott & White Medical Center, Temple
Baylor College of Medicine, Houston
Renovatio Clinic, The Woodlands
AOU Federico II, Napoli
Klinikum der Universität München, Medizinische Klinik und Poliklinik III, München
Klinikum rechts der Isar der Technischen Universität München, München
St. Joseph's Hospital and Medical Cancer Center, Phoenix
New Mexico Cancer Care Alliance, Albuquerque
UCLA, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
Hopital BEAUJON, Clichy
UC Davis Comprehensive Cancer Center, Sacramento
Virginia Mason Medical Center, Seattle
University of Washington Medical Center, Seattle
Peking Union Medical College Hospital, Dongcheng
Huashan Hospital affiliated with Fudan University, Jing’an
Groupe Hospitalier Pitié Salpêtrière, Paris
Meir Medical center, Kfar Saba
Rabin Medical Center, Petah Tikva
Shamir Medical center Asaf Harofeh, Be’er Ya‘aqov
Hadassah University Hospital Ein Kerem, Jerusalem
Yale New Haven Hospital, New Haven
Maine Health Cancer Care, South Portland
University of Massachusetts, Worcester
The Ottawa Hospital, Ottawa
Sunnybrook Health Sciences Centre, Toronto
Princess Margaret Cancer Centre/University Health Network, Toronto
McGill University Health Center, Montreal
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital Of Xi'an Jiaotong University, Xi'an
West China Hospital of Sichuan University, Chengdu
Jiangsu Province Hospital, Nanjing
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Xinhua Hospital Affiliated to Shanghai Jiaotong University School Of Medicine, Shanghai
Technische Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Hospital Universitaro Vall D'Hebron, Barcelona
University College London Hospitals NHS Foundation Trust, London
Imperial College Healthcare NHS Trust, London
Lead Sponsor
FibroGen
INDUSTRY